Prednisone Tapering in RA, Prof C Gabay, 27.10.20

1. Prednisone Tapering in RA
2. The Story of Prednisone in RA – Back to 1948
3. Glucocorticoids in RA Management
4. A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients With RA Who Achieved Low Disease Activity or Remission on Tocilizumab
5. SEMIRA (Steroid EliMination In RA) RCT: Objectives
6. Study Design
7. Patient Demographics and Characteristics at Randomization
8. Primary Efficacy End Point Change From Randomization to Week 24 in DAS28 ESR
9. Secondary Efficacy End Point: RA Flare
10. Key Secondary Efficacy End Point: Treatment Success
11. Safety and Tolerability: Summary
12. Conclusions (I)
13. Conclusions (II) Limitations
14. Comparison of oral glucocorticoid tapering in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: a population based observational cohort study Lauper K, Mongin D, …, Courvoisier DS, Finckh A, Gabay C (submitted)
15. GC treatment survival curves
16. Hazard ratios of GC discontinuation as compared to TNF inhibitors
17. Change in disease activity following GC discontinuation
18. Conclusions
19. Glucocorticoids Related Risks
20. Change in DAS28 ESR From Baseline to Week 24:
21. Flowchart : Pre Randomization

FINISH

SUBMIT

Title